Abstract:Abstract Background Glioma is the most common intracranial malignancy with a poor prognosis. Although remarkable advances have been made in the study of diagnostic and prognostic biomarkers, the efficacy of current treatment strategies is still unsatisfactory. Therefore, developing novel and reliable targets is desperately needed for glioma patients. Pyroptosis reshapes tumor immune microenvironment (TME) and promotes the destruction of the tumor by the immune system. Moreover, pyroptosis levels correlate with prognosis and immunotherapy response in many cancer patients. This study performed a comprehensive analysis of pyroptosis in the glioma, unveiling its potential value in glioma prognosis prediction and therapy efficacy. Methods Firstly, the pyroptosis regulation patterns were comprehensively evaluated on 33 pyroptosis-related genes in 1716 glioma samples. The correlations were analyzed between pyroptosis regulation patterns and TME immune cell infiltration properties. Next, pyroptosis regulation patterns were measured by the PSscore model based on principal component analysis algorithms. The correlations were analyzed between PSscore and tumor mutational burden (TMB), immune checkpoint blockade (ICB) therapeutic advantages. Last, the findings were validated in an independently collected external clinical cohort. Results We determined two distinct pyroptosis regulation patterns. The cluster-A was high immune cell infiltration with a poor prognosis ( p < 0.001), whereas the cluster-B was low immune cell infiltration with a better prognosis ( p < 0.001). We developed the PSscore as a measure for pyroptosis regulation patterns. The high PSscore with an inflamed TME phenotype, a high TMB ( p < 0.0001), increased innate immune response, and a poor prognosis ( p < 0.001). It was in stark contrast to the low PSscore ( p < 0.001). Analysis of PSscore with checkpoint therapy indicated high PSscore were correlated with enhanced response to anti-PD-1 immunotherapy ( p = 0.0046). For validation, we utilized in vitro experiments on an external clinical cohort. The results demonstrated that GSDMD expression level in the high PSscore group was significantly upregulated compared to the low PSscore group ( p < 0.001); the CD3+ T cells and the CD3+PD-1+ cells significantly increased in the high PSscore group compared to the low PSscore group ( p < 0.01). Conclusions The PSscore of pyroptosis regulation pattern is a reliable biomarker, and it is valuable to predict prognosis, TME, and ICB therapeutic efficiency in glioma patients.

PSMC2 Promotes Glioma Progression by Regulating Immune Microenvironment and PI3K/AKT/mTOR Pathway

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

PSMD12 promotes glioma progression by upregulating the expression of Nrf2

PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma

PSMB2 plays an oncogenic role in glioma and correlates to the immune microenvironment

Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration

PSMC2 Promotes the Progression of Gastric Cancer Via Induction of RPS15A/mTOR Pathway

Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration

Relationship between the expression of PSMB2 and proliferation and invasion in glioma

PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway

PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma

Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway

Comprehensive analysis of pyroptosis regulation patterns and their influence on tumor immune microenvironment and patient prognosis in glioma

PSMC2/CCND1 Axis Promotes Development of Ovarian Cancer Through Regulating Cell Growth, Apoptosis and Migration.

The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization

SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells

Tumor-Promoting Function Of Pimreg In Glioma By Activating The Beta-Catenin Pathway

PCBP2 Reduced Oxidative Stress-Induced Apoptosis in Glioma through cGAS/STING Pathway by METTL3-Mediated m6A Modification

Skp2 Modulates Proliferation, Senescence and Tumorigenesis of Glioma

MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma

PRMT2 Links Histone H3R8 Asymmetric Dimethylation to Oncogenic Activation and Tumorigenesis of Glioblastoma